The partners will provide services from complex oncology genomic testing to core central laboratory analysis, project and data management, and sample logistics on a global basis. They will leverage Cancer Genetics' expertise in genomics and other technologies focused on cancer and Icon's know-how in strategic development and management, as well as the analysis of lab data from large-scale clinical programs.
The partnership is focused on providing a "comprehensive, integrated, and efficient solution for laboratory testing for global oncology trials from Phase I through Phase IV," they said in a statement.
Financial and other terms of the deal were not disclosed.
"This partnership will satisfy the enormous need among biotech and pharmaceutical companies for more efficient and comprehensive testing solutions by integrating [Cancer Genetics'] specialized, genomic testing [into] Icon's laboratory solutions," Cancer Genetics CEO Panna Sharma said.